We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

53 hedge funds and large institutions have $84M invested in Carisma Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

387% more capital invested

Capital invested by funds: $17.3M → $84M (+$66.8M)

237% more call options, than puts

Call options by funds: $5.49M | Put options by funds: $1.63M

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

43% more funds holding

Funds holding: 37 → 53 (+16)

9.96% more ownership

Funds ownership: 13.84% → 23.8% (+10%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
53
Holders Change
+16
Holders Change %
+43.24%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
25
Increased
15
Reduced
6
Closed
9
Calls
$5.49M
Puts
$1.63M
Net Calls
+$3.86M
Net Calls Change
+$2.74M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.99M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$5.14M
3
State Street
State Street
Massachusetts
+$2.41M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.29M
5
Northern Trust
Northern Trust
Illinois
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$1.28M
2
DCM
Deuterium Capital Management
Florida
-$159K
3
WIM
Wittenberg Investment Management
Massachusetts
-$145K
4
Millennium Management
Millennium Management
New York
-$111K
5
SWP
Stratos Wealth Partners
Ohio
-$61.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
CIBC Asset Management
26
CIBC Asset Management
Ontario, Canada
$131K – – –
Connor, Clark & Lunn Investment Management (CC&L)
27
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$130K – – –
Mirae Asset Global Investments
28
Mirae Asset Global Investments
South Korea
$125K +$77.5K +14,244 New
MIM
29
MetLife Investment Management
New Jersey
$124K +$77.2K +14,186 New
AIG
30
American International Group
New York
$113K +$69.9K +12,834 New
Manulife (Manufacturers Life Insurance)
31
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$97K +$60.2K +11,059 New
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$96.5K +$59.9K +11,000 New
VOYA Investment Management
33
VOYA Investment Management
Georgia
$94.9K +$58.9K +10,822 New
Wells Fargo
34
Wells Fargo
California
$92.9K +$54.9K +10,083 +1,958%
CL
35
CSS LLC
Illinois
$92K -$327 -60 -0.6%
Invesco
36
Invesco
Georgia
$90.1K +$56K +10,279 New
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$90K +$55.9K +10,259 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$77.8K +$48.3K +8,869 New
Citigroup
39
Citigroup
New York
$69.7K +$43.2K +7,942 New
Group One Trading
40
Group One Trading
Illinois
$64.5K -$32.9K -6,042 -45%
Barclays
41
Barclays
United Kingdom
$46.6K +$28.9K +5,312 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$24K +$14.2K +2,616 +1,585%
AB
43
Amalgamated Bank
New York
$23K +$14.1K +2,594 New
Legal & General Group
44
Legal & General Group
United Kingdom
$22.5K +$14K +2,567 New
AIP
45
Ameritas Investment Partners
Nebraska
$19.3K +$12K +2,202 New
TRCT
46
Tower Research Capital (TRC)
New York
$15.2K +$7.56K +1,389 +407%
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$12.9K +$8K +1,470 New
IA
48
IFP Advisors
Florida
$1.81K -$22.5K -4,140 -95%
OP
49
ORG Partners
Indiana
$1.68K +$1.09K +200 New
AA
50
Ancora Advisors
Ohio
$570 – – –
1
2
3

CARM Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2023, worth a combined $84M — up 387% from $17.3M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CARM positions and 9 closed out — a net gain of 16 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $8.99M. The largest seller was BML Capital Management, exiting entirely with an estimated $1.28M sold.

  • 53 institutional investors held Carisma Therapeutics (CARM) as of Q2 2023, up from 37 in Q1 2023.
  • Funds reported $84M of Carisma Therapeutics stock for Q2 2023, up 387% quarter-over-quarter.
  • 25 funds opened new Carisma Therapeutics positions in Q2 2023 and 9 closed out, a net change of +16 holders.
  • The largest Carisma Therapeutics buyer in Q2 2023 was BlackRock, an estimated $8.99M added.
  • The largest Carisma Therapeutics seller in Q2 2023 was BML Capital Management, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2023.